SCHEMBL2425554

SCHEMBL2425554

O=C(O)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 10/20 0.78
DRD4 P21917 3/20 0.72
DRD2 P14416 1/20 0.72
DRD3 P35462 1/20 0.72
KMT2A Q03164 1/20 0.72
POLB P06746 2/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
DPP7 Q9UHL4 1/20 0.70
TMEM97 Q5BJF2 2/20 0.67
SLC6A12 P48065 1/20 0.67
MCHR1 Q99705 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
CYP2C9 P11712 1/20 0.67
TSHR P16473 1/20 0.67
MAPK1 P28482 1/20 0.67
CYP2C19 P33261 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21410212 0.98 SIGMAR1 (0.76) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL4298575 0.94 SIGMAR1 (0.70) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL3552998 0.92 SIGMAR1 (0.67) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL3946017 0.91 MCHR1 (0.70) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL17961749 0.91 DRD4 (0.70) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL19614234 0.91 DRD4 (0.70) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL20183285 0.91 DRD4 (0.70) SIGMAR1DRD4DRD2DRD3KMT2A
Oxalic Acid SCHEMBL1624809 0.88 DRD4 (0.67) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL20640315 0.88 SIGMAR1 (0.73) SIGMAR1DRD4DRD2DRD3KMT2A
SCHEMBL5230894 0.88 SIGMAR1 (0.74) SIGMAR1DRD4DRD2DRD3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118561742-A Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2024-08-30 CN claimed
WO-2023101252-A1 OPHTHALMIC NANOEMULSION COMPOSITION FOR TREATING MACULAR DEGENERATION AND METHOD FOR PREPARING SAME 인제대학교 산학협력단 2023-06-08 WO claimed
EP-0885239-B1 NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS BATRA SATISH (SE) 2002-08-07 EP claimed
EP-4637926-A1 SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS Universität Regensburg (DE) 2025-10-29 EP disclosed
WO-2025108255-A1 POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2025-05-30 WO disclosed
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2024-10-31 US disclosed
CN-118561742-A Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2024-08-30 CN disclosed
US-12054494-B2 Compound with anticancer activity KYOWA KIRIN CO., LTD. (JP) 2024-08-06 US disclosed
WO-2024132278-A1 SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS UNIVERSITÄT REGENSBURG (DE) 2024-06-27 WO disclosed
EP-4389223-A1 SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS Universität Regensburg (DE) 2024-06-26 EP disclosed
EP-3778573-B1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO LTD (JP) 2024-04-24 EP disclosed
WO-1997027211-A1 NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS BATRA SATISH (SE) 1997-07-31 WO disclosed
US-5595872-A DNA SEQUENCES, CELLS AND EXPRESSION VECTORS BRISTOL-MYERS SQUIBB COMPANY (US) 1997-01-21 US disclosed
WO-1996026205-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1996-08-29 WO disclosed
EP-0643057-A1 Inhibitors of microsomal triglyceride transfer protein BRISTOL-MYERS SQUIBB COMPANY (US) 1995-03-15 EP disclosed
EP-0537201-A1 IMIDAZOLYLBENZOYL SUBSTITUTED HETEROCYCLES SCHERING AKTIENGESELLSCHAFT (DE) 1993-04-21 EP disclosed
US-5189036-A Cardiovascular agents; class III antiarrhythmic agents SCHERING AG (DE) 1993-02-23 US disclosed
EP-0467325-A2 Carbostyril derivatives SYNTEX (U.S.A.) INC. (US) 1992-01-22 EP disclosed
US-5082847-A Antiarrhythmia SYNTEX (U.S.A.) INC. (US) 1992-01-21 US disclosed
WO-1991019709-A1 IMIDAZOLYLBENZOYL SUBSTITUTED HETEROCYCLES SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054494-B2 Compound with anticancer activity TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SIGMAR1 3359/4885DRD4 3651/4885DRD2 4053/4885
US-20240360149-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SIGMAR1 3359/4885DRD4 3651/4885DRD2 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.